Toripalimab Approved for First-Line Treatment of Patients With Nasopharyngeal Carcinoma

The US Food and Drug Administration (FDA) has granted approval to toripalimab-tpzi with cisplatin and gemcitabine for the treatment of patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting; and toripalimab as a single-agent for patients with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy.

Access the full article to read more here.